


### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

### **Listing of Claims:**

**Claim 1** (original): A combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide having the formula I



(I)

in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier.

**Claim 2** (original): A combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide having the formula I in which the active ingredients (a) and (b) are present in a synergistically effective amount in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier.

**Claim 3** (currently amended): Use of a combination according to claim 1 or 2 in the treatment of a tumor disease.

**Claim 4** (currently amended): Use of a combination according to ~~any one of claims 1 or 2~~claim 1 for the preparation of a medicament in the treatment of a tumor disease.

**Claim 5** (currently amended): Use of a combination according to claim 3 ~~or 4~~ wherein the tumor disease is leukemia.

**Claim 6** (currently amended): Use of a combination according to ~~any one of~~ claim 5 wherein the leukemia is a Bcr/Abl-positive leukemia.

**Claim 7** (original): Use of a combination according to claim 6 wherein the Bcr/Abl-positive leukemia is a compound of formula I-resistant leukemia.

**Claim 8** (original): Use of a combination according to claim 7 wherein the Bcr/Abl-positive leukemia resistant to compound of formula I over-expresses Bcr/Abl.

**Claim 9** (currently amended): Use or combination according to ~~any one of claims 1 to 8~~claim 1 wherein the cyclin-dependent kinase inhibitor is selected from the group consisting of purine-based derivatives, pyridimine-based derivatives, benzenesulfonamides, flavonoids, thiazole derivatives, paullone derivatives, staurosporine derivatives, indigoid bisindoles, butyrolactone 1, pyrazolopyridine compounds, indol derivatives and amino-pyrazole compounds.

**Claim 10** (currently amended): Use or combination according to ~~any one of claims 1 to 9~~claim 1 wherein the cyclin-dependent kinase inhibitor is flavopiridol or E 7070 or CYC 202.

**Claim 11** (currently amended): Use or combination according to ~~any one of claims 1 to 4~~claim 1 wherein the cyclin-dependent kinase inhibitor is flavopiridol.

**Claim 12** (original): Use or combination according to claim 11 wherein flavopiridol and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide are present in a synergistically effective molar ratio (FP/COMPOUND I) range of 1:1 to 1:10.

**Claim 13** (currently amended): A method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination according to ~~any one of claims 1 to 12~~claim 1 in a quantity which is jointly therapeutically effective against said proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

**Claim 14** (currently amended): A method of inhibiting the formation of metastases in a warm-blooded animal having a tumor disease which comprises administering to the patient a pharmaceutically effective amount of a combination according to ~~any one of claims 1 to 13~~claim 1 in a quantity which is jointly therapeutically effective against said tumor disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

**Claim 15** (currently amended): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a tumor disease of a pharmaceutical combination according to claim 1 ~~to 12~~ and at least one pharmaceutically acceptable carrier.

**Claim 16** (currently amended): A commercial package comprising a combination according to ~~any one of claims 1 to 12~~claim 1 together with instructions for simultaneous, separate or sequential use thereof in the treatment of a proliferative disease.